A single-cycle adenovirus type 7 vaccine for prevention of acute respiratory disease

Brianna L. Bullard, Brigette N. Corder, Eric A. Weaver

Research output: Contribution to journalArticle

Abstract

Adenovirus type 7 (Ad7) infection is associated with acute respiratory disease (ARD), especially in military recruits living in close quarters. Recently, several outbreaks of Ad7 infections have occurred in civilian populations, with some cases leading to death. However, the current Ad7 vaccine is licensed for use only in military recruits because it utilizes an orally delivered wild type virus which is shed in the stool for 28 days after immunization. This poses a safety risk due to the possibility of virus spread to vulnerable populations. To address the need for a safer Ad7 vaccine for use in civilian populations, we developed a single-cycle Ad7 virus (scAd7). This scAd7 virus is deleted for the Ad7 fiber protein, so that viruses produced outside of complementing cells lines lack this essential structural protein and have severely reduced infectivity. In vitro studies in noncomplementing A549 cells showed that the scAd7 virus has genomic DNA replication kinetics and Ad7 hexon expression similar to a replication-competent virus; however, virus progeny produced after infection has impaired infectivity. Therefore, this scAd7 virus combines the safety advantages of a replication-defective virus with the increased Ad7 gene expression of a replication-competent virus. Due to these advantages, we believe that scAd7 viruses should be further studied as an alternative, safer Adenovirus 7 vaccine.

Original languageEnglish (US)
Article number413
JournalViruses
Volume11
Issue number5
DOIs
StatePublished - May 2019

Fingerprint

Adenovirus Vaccines
Acute Disease
Viruses
Adenoviridae
Adenoviridae Infections
Virus Replication
Defective Viruses
Safety
Vulnerable Populations

Keywords

  • ARD
  • Acute respiratorydisease
  • Adenovirus
  • Military
  • Pediatricdeaths
  • Single cycle
  • Type 7
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

A single-cycle adenovirus type 7 vaccine for prevention of acute respiratory disease. / Bullard, Brianna L.; Corder, Brigette N.; Weaver, Eric A.

In: Viruses, Vol. 11, No. 5, 413, 05.2019.

Research output: Contribution to journalArticle

Bullard, Brianna L. ; Corder, Brigette N. ; Weaver, Eric A. / A single-cycle adenovirus type 7 vaccine for prevention of acute respiratory disease. In: Viruses. 2019 ; Vol. 11, No. 5.
@article{01bb17c0129b422c9dac23acc98283c4,
title = "A single-cycle adenovirus type 7 vaccine for prevention of acute respiratory disease",
abstract = "Adenovirus type 7 (Ad7) infection is associated with acute respiratory disease (ARD), especially in military recruits living in close quarters. Recently, several outbreaks of Ad7 infections have occurred in civilian populations, with some cases leading to death. However, the current Ad7 vaccine is licensed for use only in military recruits because it utilizes an orally delivered wild type virus which is shed in the stool for 28 days after immunization. This poses a safety risk due to the possibility of virus spread to vulnerable populations. To address the need for a safer Ad7 vaccine for use in civilian populations, we developed a single-cycle Ad7 virus (scAd7). This scAd7 virus is deleted for the Ad7 fiber protein, so that viruses produced outside of complementing cells lines lack this essential structural protein and have severely reduced infectivity. In vitro studies in noncomplementing A549 cells showed that the scAd7 virus has genomic DNA replication kinetics and Ad7 hexon expression similar to a replication-competent virus; however, virus progeny produced after infection has impaired infectivity. Therefore, this scAd7 virus combines the safety advantages of a replication-defective virus with the increased Ad7 gene expression of a replication-competent virus. Due to these advantages, we believe that scAd7 viruses should be further studied as an alternative, safer Adenovirus 7 vaccine.",
keywords = "ARD, Acute respiratorydisease, Adenovirus, Military, Pediatricdeaths, Single cycle, Type 7, Vaccine",
author = "Bullard, {Brianna L.} and Corder, {Brigette N.} and Weaver, {Eric A.}",
year = "2019",
month = "5",
doi = "10.3390/v11050413",
language = "English (US)",
volume = "11",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - A single-cycle adenovirus type 7 vaccine for prevention of acute respiratory disease

AU - Bullard, Brianna L.

AU - Corder, Brigette N.

AU - Weaver, Eric A.

PY - 2019/5

Y1 - 2019/5

N2 - Adenovirus type 7 (Ad7) infection is associated with acute respiratory disease (ARD), especially in military recruits living in close quarters. Recently, several outbreaks of Ad7 infections have occurred in civilian populations, with some cases leading to death. However, the current Ad7 vaccine is licensed for use only in military recruits because it utilizes an orally delivered wild type virus which is shed in the stool for 28 days after immunization. This poses a safety risk due to the possibility of virus spread to vulnerable populations. To address the need for a safer Ad7 vaccine for use in civilian populations, we developed a single-cycle Ad7 virus (scAd7). This scAd7 virus is deleted for the Ad7 fiber protein, so that viruses produced outside of complementing cells lines lack this essential structural protein and have severely reduced infectivity. In vitro studies in noncomplementing A549 cells showed that the scAd7 virus has genomic DNA replication kinetics and Ad7 hexon expression similar to a replication-competent virus; however, virus progeny produced after infection has impaired infectivity. Therefore, this scAd7 virus combines the safety advantages of a replication-defective virus with the increased Ad7 gene expression of a replication-competent virus. Due to these advantages, we believe that scAd7 viruses should be further studied as an alternative, safer Adenovirus 7 vaccine.

AB - Adenovirus type 7 (Ad7) infection is associated with acute respiratory disease (ARD), especially in military recruits living in close quarters. Recently, several outbreaks of Ad7 infections have occurred in civilian populations, with some cases leading to death. However, the current Ad7 vaccine is licensed for use only in military recruits because it utilizes an orally delivered wild type virus which is shed in the stool for 28 days after immunization. This poses a safety risk due to the possibility of virus spread to vulnerable populations. To address the need for a safer Ad7 vaccine for use in civilian populations, we developed a single-cycle Ad7 virus (scAd7). This scAd7 virus is deleted for the Ad7 fiber protein, so that viruses produced outside of complementing cells lines lack this essential structural protein and have severely reduced infectivity. In vitro studies in noncomplementing A549 cells showed that the scAd7 virus has genomic DNA replication kinetics and Ad7 hexon expression similar to a replication-competent virus; however, virus progeny produced after infection has impaired infectivity. Therefore, this scAd7 virus combines the safety advantages of a replication-defective virus with the increased Ad7 gene expression of a replication-competent virus. Due to these advantages, we believe that scAd7 viruses should be further studied as an alternative, safer Adenovirus 7 vaccine.

KW - ARD

KW - Acute respiratorydisease

KW - Adenovirus

KW - Military

KW - Pediatricdeaths

KW - Single cycle

KW - Type 7

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85065662262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065662262&partnerID=8YFLogxK

U2 - 10.3390/v11050413

DO - 10.3390/v11050413

M3 - Article

C2 - 31058858

AN - SCOPUS:85065662262

VL - 11

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 5

M1 - 413

ER -